Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Malate Plus Lutetium Lu 177 Dotatate in Pancreatic Neuroendocrine Tumors
NCT05687123Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sunitinib and lutetium Lu 177 dotatate in Pancreatic neuroendocrine tumor (PanNET), sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events at 8 weeks. Started Aug 2024; status: recruiting.
02
Drugs
sunitiniblutetium Lu 177 dotatate
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT05687123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687123.